Kisspeptin Research Guide: Mechanism, Trials and Regulatory Status

Kisspeptin-producing neurons cluster in two hypothalamic regions — the arcuate nucleus and the anteroventral periventricular/rostral periventricular area — and project onto gonadotropin-releasing hormone (GnRH) neurons, where kisspeptin binding to KISS1R triggers GnRH release. GnRH then travels to the pituitary gland and drives release of luteinising hormone (LH) and follicle-stimulating hormone (FSH), the two hormones that direct oestrogen, progesterone and testosterone production by the ovaries and testes.^[2][3]

Because every downstream step depends on this trigger, the same 2003 mutation studies that identified KISS1R's role describe kisspeptin signalling as the gatekeeper of puberty onset and the ongoing reproductive cycle, sitting upstream of the entire hypothalamic-pituitary-gonadal axis. That single position — one signal controlling the whole cascade — is why kisspeptin has been the target of the human physiology studies described below, rather than a therapy aimed at any one downstream hormone.^[2][3]

The best-known human application of kisspeptin comes from IVF research in women at high risk of ovarian hyperstimulation syndrome (OHSS), a complication of the hormone triggers conventionally used to mature eggs before retrieval. In a phase 2, open-label, adaptive-dose randomised trial of 60 women at Hammersmith Hospital, London, each participant received a single injection of kisspeptin-54, at one of four doses, in place of the standard hCG or GnRH-agonist trigger. At least one mature egg was retrieved in 95% of cycles (57 of 60), with an overall oocyte maturation rate of 74% and a fertilisation rate of 74% across all dose groups.^[4]

A follow-on phase 2 randomised controlled trial by the same research group later tested a second kisspeptin-54 injection, given some hours after the first, in the same OHSS-risk IVF population, and reported improved oocyte maturation compared with a single dose. Both trials studied kisspeptin-54 strictly as an investigational trigger within a supervised IVF protocol, not as a self-administered fertility treatment.^[5]

Hypothalamic amenorrhoea (HA) is a condition in which the brain under-drives the reproductive axis — often linked to low energy availability, psychological stress or high exercise load — halting the menstrual cycle. In the first human kisspeptin trial in this population, women with HA received subcutaneous injections of kisspeptin-54; a single injection acutely raised LH roughly 10-fold and FSH roughly 2.5-fold, but when the same dose was repeated over two weeks, the gonadotropin response weakened — a published finding the researchers described as tachyphylaxis, not a treatment outcome.^[6]

A later study in five women with HA tested continuous intravenous infusion instead of injection, at escalating doses against a vehicle infusion. Kisspeptin-54 increased the mean peak number of LH pulses roughly 3-fold (5.0 vs 1.6 pulses per 8 hours with vehicle) and the mean peak LH pulse secretory mass roughly 6-fold compared with vehicle. Together, the two studies show kisspeptin can acutely restore pulsatile LH signalling in HA; neither describes a demonstrated long-term therapy.^[7]

Kisspeptin neurons also project into limbic brain structures, which prompted a separate line of human research into brain processing rather than reproductive hormones alone. In a double-blind, placebo-controlled, crossover fMRI study of 29 heterosexual men, a single dose of kisspeptin — compared with placebo — heightened activity in limbic structures including the amygdala in response to sexual and couple-bonding imagery, and separately increased activity in structures associated with mood regulation in response to negative imagery, alongside lower participant-reported negative mood after scanning.^[8]

Two later double-blind, placebo-controlled, crossover randomised trials extended this work to clinical populations: 40 women (published 2022) and 32 men (published 2023), each diagnosed with hypoactive sexual desire disorder (HSDD). Using fMRI alongside behavioural and hormonal measures, a single dose of kisspeptin was associated with favourable shifts in sexual and emotional brain processing in both trials; in the men's trial specifically, kisspeptin increased participant-reported happiness about sex compared with placebo, and the compound was reported as well tolerated in these short, single-dose sessions, with no adverse events recorded.^[9][10]

No kisspeptin formulation has been tested in a phase 3 trial, for any of the uses described above. The 2009 hypothalamic-amenorrhoea study itself published tachyphylaxis — a weakening biological response — with repeated subcutaneous dosing, which is exactly the kind of finding a later-phase programme would need to resolve before kisspeptin could move from research probe to therapy.^[6]

The furthest-developed kisspeptin-receptor drug candidate, MVT-602, has published endocrine-profile data from two randomised, placebo-controlled phase 2 trials in healthy premenopausal women, including women undergoing ovarian stimulation; no phase 3 results are published. The brain-imaging and hypoactive-sexual-desire-disorder studies above are single-dose, short-duration trials in samples of under 40 participants; whether repeated dosing sustains any effect, or whether kisspeptin changes a diagnosed condition over weeks or months, has not been published.^{[11][8][9][10]}

As of September 2026, no kisspeptin-based product holds a marketing authorisation from the European Medicines Agency or an approval from the US Food and Drug Administration for any indication; every human study cited in this article was conducted under a clinical-trial authorisation, not as an approved medicine.^[12][13]

Peptyds does not sell kisspeptin or any kisspeptin analogue. This article summarises the published research literature for readers who want to understand the science; it is not a product page, and nothing in it is an offer, a recommendation, or instructions for personal use.